Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug

Stock Track09:46

LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.

The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.

Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152091097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152091097","market":"sg","top_or_hot":-1,"title":"Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug","media":"Stock Track","content":"<p>LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.</p><p>The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.</p><p>Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-09 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.</p><p>The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.</p><p>Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1152091097","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152091097","pubTimestamp":1775699209,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.The company announced that the preliminary safety evaluation for the Phase II...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"个股追踪|胆道癌药物II期临床试验结果积极领涨BIOLABS-B盘中大涨5.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152091097","isCrawlerRequest":true}